The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic factors in patients with WHO grade 3 gliomas: The Cleveland Clinic experience.
N. Hashemi-Sadraei
No relevant relationships to disclose
H. S. Bawa
No relevant relationships to disclose
A. Satra
No relevant relationships to disclose
G. Rahmathulla
No relevant relationships to disclose
M. Patel
No relevant relationships to disclose
G. Stevens
No relevant relationships to disclose
T. M. Tekautz
No relevant relationships to disclose
L. A. Rybicki
No relevant relationships to disclose
D. M. Peereboom
No relevant relationships to disclose
J. H. Suh
No relevant relationships to disclose
R. Weil
No relevant relationships to disclose
M. A. Vogelbaum
Consultant or Advisory Role - Ark Therapeutics; AstraZeneca; Schering-Plough
G. Barnett
Consultant or Advisory Role - Monteris Medical
M. S. Ahluwalia
Consultant or Advisory Role - Monteris Medical
Honoraria - Cephalon